You are here

Alzheimer's disease

After Biogen Deal Fizzles, Rodin Bags $27M And Heads To First Trial

After Biogen Deal Fizzles, Rodin Bags $27M And Heads To First Trial

Xconomy

Rodin Therapeutics

Alzheimer's disease

clinical trials

Flag link:

The billion-dollar gamble: Biotech CEO takes a risky second shot at an Alzheimer’s drug

The billion-dollar gamble: Biotech CEO takes a risky second shot at an Alzheimer’s drug

Stat

Alzheimer's disease

Flag link:

Upcoming events – GSK’s shingles panel and Axovant takes on Alzheimer’s

Upcoming events – GSK’s shingles panel and Axovant takes on Alzheimer’s

EP Vantage

Alzheimer's disease

Flag link:

Biogen gains over 1 billion in capitalization thanks to Alzheimer’s pipeline

Biogen gains over 1 billion in capitalization thanks to Alzheimer’s pipeline

GoInPharma

Alzheimer's disease

Flag link:

New target could yield treatment for Alzheimer's, ALS and more

New target could yield treatment for Alzheimer's, ALS and more

Fierce Biotech

drug development

Alzheimer's disease

Flag link:

Neurotrope stock tumbles again on Alzheimer's data

Neurotrope stock tumbles again on Alzheimer's data

BioPharma Dive

Neurotrope BioScience

Alzheimer's disease

Flag link:

New data from Alzheon shows long-term benefit for Alzheimer's

New data from Alzheon shows long-term benefit for Alzheimer's

BioPharma Dive

Alzheimer's disease

Flag link:

5 trends shaping Alzheimer's drug development

5 trends shaping Alzheimer's drug development

BioPharma Dive

Alzheimer's disease

drug development

Flag link:

Big Pharma VCs jump in to back a $63M mission to tackle a genetic driver of Alzheimer’s

Big Pharma VCs jump in to back a $63M mission to tackle a genetic driver of Alzheimer’s

Endpoints

venture capital

Alzheimer's disease

Flag link:

Alzheon says data backs potential of Alzheimer's candidate

Alzheon says data backs potential of Alzheimer's candidate

PM Live

Alzheimer's disease

Flag link:

Alzheimer’s Drug Pipeline Analysis: Have We Hit Peak Amyloid?

Alzheimer’s Drug Pipeline Analysis: Have We Hit Peak Amyloid?

Xconomy

Alzheimer's disease

Flag link:

Alzheimer's Affects Twice As Many People As Estimated, Says New Study

Alzheimer's Affects Twice As Many People As Estimated, Says New Study

Forbes

Alzheimer's disease

Flag link:

In small Alzheimer’s study, hints of modest benefit from unusual drug

In small Alzheimer’s study, hints of modest benefit from unusual drug

Stat

Alzheimer's disease

Neurotrope BioScience

Flag link:

Novartis Tests New Alzheimer's Drugs on People Who Don't Have the Disease

Novartis Tests New Alzheimer's Drugs on People Who Don't Have the Disease

FOX Business

Alzheimer's disease

Flag link:

A company developing a drug to treat Alzheimer's disease just got a new CEO — and the stock is jumping

A company developing a drug to treat Alzheimer's disease just got a new CEO — and the stock is jumping

Yahoo/Business Insider

Alzheimer's disease

Axovant Sciences

Flag link:

Alzheimer's $250B Cost Could Break Medicare

Alzheimer's $250B Cost Could Break Medicare

Forbes

Alzheimer's disease

Flag link:

Roche is bringing back gantenerumab from the dead, taking another stab at Alzheimer’s PhIII

Roche is bringing back gantenerumab from the dead, taking another stab at Alzheimer’s PhIII

Endpoints

Alzheimer's disease

clinical trials

Flag link:

Big Pharma Is Losing a Fortune Trying to Cure Alzheimer's

Big Pharma Is Losing a Fortune Trying to Cure Alzheimer's

Bloomberg

Alzheimer's disease

drug development

Flag link:

Thumped by the FDA, Accera’s attempt to do a serious Alzheimer’s PhIII ends with a flop

Thumped by the FDA, Accera’s attempt to do a serious Alzheimer’s PhIII ends with a flop

Endpoints

Alzheimer's disease

clinical trials

Flag link:

Roche to start new trial of AC Immune drug against Alzheimer's

Roche to start new trial of AC Immune drug against Alzheimer's

Yahoo/Reuters

Alzheimer's disease

clinical trials

Flag link: